Search - tctmd.com

Displaying 401 - 420 of 783

Sort: Relevancy | Date

News Conference News ACC 2018

Salt in the Wound: Experts Clash Over Ideal Sodium Targets in Hypertension

Michael O'Riordan

March 15, 2018

News Conference News ACC 2018

PFO Closure Guided by High-Risk Features on Echo Shows Benefit in DEFENSE-PFO

Shelley Wood

March 15, 2018

News Conference News ACC 2018

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Yael L. Maxwell

March 14, 2018

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

News Conference News ACC 2018

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

Caitlin E. Cox

March 14, 2018

News Conference News ACC 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

Todd Neale

March 13, 2018

News Conference News ACC 2018

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

Yael L. Maxwell

March 12, 2018

Presentation ACC 2018

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Presenter: Brendan M. Everett

March 12, 2018

Presentation ACC 2018

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Presenter: Hyeon-Cheol Gwon

March 12, 2018

News Conference News ACC 2018

Low-Dose, Three-Drug Polypill TRIUMPHs for Blood Pressure

Shelley Wood

March 12, 2018

News Conference News ACC 2018

Mixing Haircuts and Hypertension Rx a ‘Home Run’ for Blood Pressure Control

Todd Neale

March 12, 2018

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

Presentation ACC 2018

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

Presenter: Diego Ardissino

March 12, 2018

Presentation ACC 2018

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

Presenter: Sony Tuteja

March 12, 2018

Presentation ACC 2018

A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial)

Presenter: Mehdi H. Shishehbor

March 12, 2018

News Conference News ACC 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

Todd Neale

March 12, 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticouagulants

Presentation ACC 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

Presenter: Steve Deitelzweig

March 12, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

Presentation ACC 2018

ARTEMIS: Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Presenter: Tracy Wang

March 12, 2018

Presentation ACC 2018

MANAGE: Dabigatran in Myocardial Injury After Noncardiac Surgery

Presenter: Philip Devereaux

March 12, 2018

Advertisement

Salt in the Wound: Experts Clash Over Ideal Sodium Targets in Hypertension

PFO Closure Guided by High-Risk Features on Echo Shows Benefit in DEFENSE-PFO

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Low-Dose, Three-Drug Polypill TRIUMPHs for Blood Pressure

Mixing Haircuts and Hypertension Rx a ‘Home Run’ for Blood Pressure Control

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial)

COMPASS Approach Helps With Leg Complications in Patients With PAD

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

ARTEMIS: Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

MANAGE: Dabigatran in Myocardial Injury After Noncardiac Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content